Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ONXX -- Ignore unavailable to you. Want to Upgrade?

To: Tom Hua who wrote (506)	8/4/2000 6:03:43 PM
From: Charles Tutt	Respond to of 810

I hadn't seen the article to which you refer, but was able to find it on Yahoo!. If you think the timing was sinister, I guess you're entitled to your opinion. BTW, there's a big difference between being on the board and being an officer of the company. Surely you realize that? Just for our information, do you know when Yahoo! first had him in the profile as VP? JMHO.

To: Tom Hua who wrote (506)	8/6/2000 9:15:32 AM
From: Elmer	Read Replies (1) \| Respond to of 810

Hi Tom, Remember GERON abcnews.go.com Generally, I agree with the view that the article takes which is you will get hurt buying the news. This is the first stock I've purchased on the news. The late stage trials make it different. Also, you probably remember EntreMed and the New York Times article that pushed the price from around $12 to over $80 the next morning in May of 1998. ENMD wasn't even close to trials. But check the chart. Even though they weren't close to a drug like ONXX, the stock never returned to the levels prior to the article. Again, late stage trials make it different for ONXX. As Greg pointed out, the news gets out and permanently built into the price. dbc.com